RAMPART

Current Clinical Trials

Kidney — In Follow-up

Removing the kidney (or part of a kidney) by surgery is currently the best treatment if you have kidney cancer. The current standard treatment after surgery is ‘active monitoring’. This means no further treatment, but having regular checks so that if the cancer does come back further treatment options can be considered as early as possible.

Surgery, together with ongoing regular follow-up and observation, is the standard approach for people diagnosed with kidney cancer that has required removal of the kidney (or part of a kidney) by surgery. For some people the cancer may return which is when other treatment is offered. We are aiming to find out whether taking one drug (durvalumab) or a combination of two drugs (durvalumab and tremelimumab) can prevent or delay kidney cancer coming back.

The RAMPART study is now closed in Australia after enrolling 36 patients across Australia.

If you think this trial might be right for you, please ask your doctor.

TRIAL TITLE

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi arm multi stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

CONSUMER TITLE

Study testing whether immunotherapy (durvalumab with or without tremelimumab) after kidney cancer surgery can reduce the chance of the cancer returning.

CANCER TYPE

Kidney

TRIAL STATUS

In Follow-up

PROTOCOL NUMBER

ANZUP 1606

CO-ORDINATING CENTRE

NHMRC Clinical Trials Centre

STUDY CHAIR

Professor Ian Davis

PATIENT POPULATION

Patients who have had their RCC resected and are classified as being at intermediate or high risk of recurrence (Leibovich score 3-11) are eligible for randomisation into RAMPART.